Full Breakdown
Marijuana Industry Pushes Back Against Wall Street Barriers
1/10/2026, 11:37:22 AM
Core Event: Lobbying for Banking Access Post-Trump Executive Order
The marijuana industry, represented by Pot Inc., is mobilizing to lobby the Trump administration, asserting that Wall Street's resistance is obstructing the implementation of President Donald Trump's executive order (EO) that reclassifies marijuana for medical use. Signed on December 18, the EO aims to shift marijuana from a Schedule I drug, akin to heroin, to a Schedule III classification, similar to Tylenol with codeine. However, major banks, including JPMorgan Chase, Bank of America, and Citigroup, argue that the EO does not grant them the authority to provide essential banking services to the marijuana sector, particularly for recreational use.
Background & Context: The Executive Order's Limitations
While Trump's EO is seen as a step towards legitimizing marijuana, it primarily addresses medical applications, leaving recreational use unregulated. This has led banks to maintain a cautious stance, as they claim their internal policies prevent them from engaging with the marijuana industry. A memo from JPMorgan indicated that the bank would not alter its position until marijuana is formally classified as a Schedule III drug and the law is amended accordingly. Furthermore, the New York Stock Exchange (NYSE) and Nasdaq continue to prohibit the listing of U.S.-based marijuana companies, further complicating the industry's financial landscape.
Key Figures & Groups: Advocates and Opponents
Marc Cohodes, a former hedge fund manager and cannabis investor, has emerged as a prominent advocate for the marijuana industry in light of the EO. He contends that major banks are misinterpreting the executive order and violating its intent. Cohodes emphasizes the potential for a $35 billion medical marijuana market, which he argues necessitates banking services to facilitate transactions with government programs like Medicare and Medicaid. He asserts that the industry will eventually secure banking access, regardless of current resistance from financial institutions.
Criticism & Opposition: Banking Sector's Stance
Critics, including Cohodes, argue that the banking sector's refusal to engage with the marijuana industry contradicts the spirit of Trump's EO. They highlight the irony that U.S. marijuana companies, which contribute to the economy through job creation and tax revenue, are unable to access the same financial opportunities as Canadian companies, which can list on U.S. exchanges. This disparity raises questions about the broader implications of the current regulatory framework and its impact on the growth of the marijuana industry.
Official Statements & Responses
While representatives from JPMorgan, Nasdaq, and NYSE declined to comment on the situation, Cohodes remains optimistic about the future of the marijuana industry. He stated, “The industry is going to be banked whether they want to or not because Trump wants it to be banked.” This sentiment reflects a belief that the administration will ultimately support the industry's financial integration.
What's Next: Future Developments
As Pot Inc. and its advocates continue to push for banking access, the outcome of their lobbying efforts will be crucial in determining the future of the marijuana industry in the U.S. The ongoing dialogue between industry leaders and the Trump administration may shape the regulatory landscape and influence the financial viability of marijuana businesses moving forward.
